CSS
AVDL

Cubist Systematic Strategies’s Avadel Pharmaceuticals AVDL Stock Holding History

Cubist Systematic Strategies’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-273,736
Closed -$2.42M – 3006
2025
Q2 		$2.42M Buy
273,736
+123,285
+82% +$1.08M 0.01% 1466
2025
Q1 		$1.18M Buy
+150,451
New +$1.26M 0.01% 1728
2024
Q2 		– Sell
-168,528
Closed -$2.85M – 2974
2024
Q1 		$2.85M Buy
168,528
+159,281
+1,723% +$2.37M 0.02% 1367
2023
Q4 		$131K Sell
9,247
-9,338
-50% -$110K ﹤0.01% 3118
2023
Q3 		$191K Sell
18,585
-86,029
-82% -$1.15M ﹤0.01% 2802
2023
Q2 		$1.72M Buy
104,614
+55,289
+112% +$719K 0.01% 1599
2023
Q1 		$452K Sell
49,325
-107,885
-69% -$887K ﹤0.01% 2727
2022
Q4 		$1.13M Buy
157,210
+105,401
+203% +$739K 0.01% 2336
2022
Q3 		$260K Buy
+51,809
New +$285K ﹤0.01% 3601
2022
Q1 		– Sell
-41,370
Closed -$334K – 3551
2021
Q4 		$334K Buy
41,370
+23,397
+130% +$214K ﹤0.01% 2728
2021
Q3 		$176K Buy
+17,973
New +$142K ﹤0.01% 2615
2020
Q4 		– Sell
-68,820
Closed -$347K – 2553
2020
Q3 		$347K Buy
+68,820
New +$501K 0.01% 1933
2020
Q2 		– Sell
-15,326
Closed -$122K – 2390
2020
Q1 		$122K Buy
+15,326
New +$118K ﹤0.01% 1859
2018
Q3 		– Sell
-10,820
Closed -$66K – 1883
2018
Q2 		$66K Buy
+10,820
New +$75.9K ﹤0.01% 1608
2018
Q1 		– Sell
-10,982
Closed -$90K – 1830
2017
Q4 		$90K Sell
10,982
-6,549
-37% -$61.4K ﹤0.01% 1697
2017
Q3 		$184K Buy
+17,531
New +$167K 0.01% 1481
2016
Q2 		– Sell
-3,115
Closed -$34K – 1717
2016
Q1 		$34K Buy
3,115
+3,015
+3,015% +$29.9K ﹤0.01% 1498
2015
Q4 		$1K Sell
100
-26,988
-100% -$421K ﹤0.01% 1727
2015
Q3 		$442K Buy
+27,088
New +$597K 0.02% 1031
2015
Q2 		– Sell
-15,350
Closed -$276K – 1819
2015
Q1 		$276K Buy
+15,350
New +$240K 0.01% 1309

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Cubist Systematic Strategies's AVDL Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Avadel Pharmaceuticals (AVDL) in Q3 2025, closing a stake of 273,736 shares — an estimated $2.42M sold.

Cubist Systematic Strategies first reported a position in AVDL in Q1 2015 and held it in 20 quarters. The position peaked at $2.85M in Q1 2024. 188 funds tracked by Wall St. Rank hold AVDL as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Avadel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 273,736 Avadel Pharmaceuticals shares in Q3 2025, an estimated $2.42M.
  • Cubist Systematic Strategies first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 20 quarters.
  • Cubist Systematic Strategies's Avadel Pharmaceuticals position peaked at $2.85M in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.